Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.
Nam
Hae-Seong
HS
Koh
Won-Jung
WJ
Kwon
O Jung
OJ
Cho
Sang-Nae
SN
Shim
Tae Sun
TS
D000081:Acetamides / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D003470:Culture Media; D004334:Drug Administration Schedule; D024901:Drug Resistance, Multiple, Bacterial; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D007723:Korea; D000069349:Linezolid; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D023303:Oxazolidinones / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000382:microbiology; D055815:Young Adult
D000081:Acetamides; D000890:Anti-Infective Agents; D003470:Culture Media; D023303:Oxazolidinones; D000069349:Linezolid